Insecticides India Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/f6inaihb8m8j9us7bpfcmxt9.pdf

Key Takeaways


The Chinese Price Shock

Rajesh Aggarwal: "I would say it has been the worst time, when the China has deteriorated so much and deteriorated the value of the products, which we had never imagined. So sometimes there are hits, which you don't imagine."

Margin Walk & Recovery Path

Rajesh Aggarwal: "I don't want to give the higher figures because Chinese situation overall is looking very bad, wherein as I told you that they are almost at 10 years low price, in many products, actually. And the future is not very clear. So that's why we are going a little subdued as the situation improves because it's like a wheel. The wheel is at the lowest level at the moment."

Product Portfolio & Brand Building


Capacity Expansion & Plant Updates


Export & International Dynamics

Rajesh Aggarwal: "It's a sustainable situation because every business trend is cyclic. This is the lowest phase, which we are passing through, when the international market or the Chinese market is dumping at very low cost. It is not sustainable for them. Many factories are closing."

Balance Sheet & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthDouble-digit, 10% to 12%FY24
EBITDA margin9% to 10% (described as conservative)FY24
High-cost inventory liquidationMajority liquidated, effort to complete majority in Q1Q1 FY24 / FY24
Trailing losses from higher-cost inventoryFinished by end of Q1; no impact from Q2End of Q1 FY24
ExportsDouble after FY23 declineFY24
Maharatna + Focused Maharatna contributionNot less than 60% of salesFY24
Sotanala plant Phase 1Formulations production beginsEnd of FY24
Patented product salesMultiply from ~₹100 crore base in FY23FY24

Key Metrics

MetricQ4 FY23
Revenue₹302 crore, growth of about 8.6%
EBITDA marginNegative 9.37%, due to M2M losses and liquidation of higher cost inventory
Revenue (full year FY23)₹1,801.33 crore, growth of about 19.77% YoY
EBITDA (full year FY23)₹121.89 crore
EBITDA margin (full year FY23)Declined by 451 bps YoY
Maharatna products sale₹78.6 crore, about 51% of formulation sales
Insecticide segment revenue₹72 crore, 47% of Q4 sales
Herbicide segment revenue₹43.5 crore, 29% of Q4 sales
Fungicide segment revenue₹36 crore, 23% of Q4 sales
Biologicals and PGRs revenue₹0.9 crore, 1% of sales
M2M losses (full year FY23)Around ₹14 crore
Higher cost inventory in Q4 sales70% of Q4 sales
Patented products sales (full year FY23)About ₹100 crore
Closing inventoryAbout ₹860 crore
FY24 revenue growth target10% to 12%
FY24 EBITDA margin target9% to 10%
FY24 Maharatna and Focused Maharatna contribution targetNot less than 60%
FY24 export expectationDoubling
Q1 FY24 gross sales target₹800 crore-plus
High-cost inventory liquidated~50% liquidated, ~50% still remaining
Credit note impact from dealer price protection₹15–20 crore hit
China price decline20% to 50%, some at 10–15 year lows
Interim dividend₹3 per share